Roche Holding AG (SWX: ROG)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 209.45B |
| Revenue (ttm) | 60.58B |
| Net Income (ttm) | 10.62B |
| Shares Out | 796.79M |
| EPS (ttm) | 13.24 |
| PE Ratio | 19.65 |
| Forward PE | 13.46 |
| Dividend | 9.60 (3.71%) |
| Ex-Dividend Date | n/a |
| Volume | 1,369,168 |
| Open | 258.40 |
| Previous Close | 258.50 |
| Day's Range | 257.70 - 260.30 |
| 52-Week Range | 212.90 - 288.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 18, 2024 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, Roche Holding AG's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial StatementsNews
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Scholar Rock Holding (NASDAQ: SRRK) stock is trading higher on Monday after the company released topline results from the Phase 3 SAPPHIRE trial of apitegromab in spinal muscular atrophy . The study ...
David Roche Warns Of Market Instability From Fed's 50-Basis Point Cut: 'US Economy Is Robust...Does Not Need Rock Bottom Interest Rates'
In a recent development, David Roche , a strategist at Quantum Strategy , has raised alarms over the Federal Reserve’s decision to slash interest rates by 50 basis points. What Happened : Roche argues...
David Roche says misleading 50-basis-point Fed cut will create market instability
David Roche, strategist at Quantum Strategy, says the Federal Reserve's initial jumbo cut gives markets the wrong impression that rates will return to rock bottom.
Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
Roche has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical industry's fas...
Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical ind...
Organon reports positive phase 3 results on Roche Perjuta biosimilar
Organon and Shanghai Henlius Biotech announce successful phase 3 trial of biosimilar to Roche's Perjeta for HER2-positive breast cancer treatment. Read more here.
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Poseida’s partnerships with Roche and Astellas aim to advance CAR-T therapies. See PSTX stock details and the impact of recent study results.
Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report
Roche (RHHBY) Plans to Launch 20 New Drugs to Tackle Major Societal Diseases
Roche (RHHBY) Plans to Launch 20 New Drugs to Tackle Major Societal Diseases
Roche targets more than $3 billion in annual obesity sales
Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billi...
Novo's Tough Month Key in Ending Health Stocks' Winning Streak
European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over Novo Nordisk A/S’s upcoming third-quarter results and experimental drug updates...
Roche Aims to Deliver 20 New Drugs in Research Overhaul
Roche Holding AG is aiming to deliver 20 new medicines to address diseases that rank among the biggest burdens to society this decade, as it seeks to kick-start its development program.
Roche, Biogen kidney disease drug hits main goal in late-stage study
Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Positive phase III results for Roche's Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva® ...
Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
– The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is designed to targe...
Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints
Roche narrows pipeline to 11 disease areas amidst weight loss push - WSJ
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
Basel, 24 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the cobas® Respiratory flex test, the first to use Roche's novel and proprietary TAGS (Temperature-Activated...
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche's role in pioneering cervical cancer solutions
Basel, 23 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the World Health Organization (WHO) has included dual-stain cytology testing in its cervical cancer prevention guidel...
Roche’s chairman says government subsidies waste money
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA...
Roche unit hits main goal in late-stage trial for flu therapy
Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the transmission of influzenza virus. Read more here.
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluz...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Basel, 19 September - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reduction...